Researchers develop mutant gene-targeted immunotherapy approach to fight cancers

A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer…

Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC?

The checkpoint inhibitor nivolumab is efficacious and well tolerated when used as adjuvant therapy in patients who have undergone radical…